Oral Ezatiostat HCl (TLK199) and Myelodysplastic syndrome: A case report of sustained hematologic response following an abbreviated exposure

Treatment options for patients with lower risk non-del(5q) myelodysplastic syndromes (MDS) who fail erythroid stimulating agents are restricted to one of the hypomethylating drugs with an expected response rate of ~50%. Ezatiostat HCl, an agent with the potential for producing multi-lineage response...

Descripción completa

Detalles Bibliográficos
Autores principales: Quddus, Fahd, Clima, Jessica, Seedham, Helen, Sajjad, Ghulam, Galili, Naomi, Raza, Azra
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2010
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2873355/
https://www.ncbi.nlm.nih.gov/pubmed/20416051
http://dx.doi.org/10.1186/1756-8722-3-16

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2873355/
https://www.ncbi.nlm.nih.gov/pubmed/20416051
http://dx.doi.org/10.1186/1756-8722-3-16

Ejemplares similares